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Unusual substrate and halide versatility of phenolic
halogenase PltM
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Shogo Mori1, Allan H. Pang1, Nishad Thamban Chandrika1, Sylvie Garneau-Tsodikova1 & Oleg V. Tsodikov1

Controlled halogenation of chemically versatile substrates is difﬁcult to achieve. Here
we describe a unique ﬂavin-dependent halogenase, PltM, which is capable of utilizing a
wide range of halides for installation on a diverse array of phenolic compounds, including
FDA-approved drugs and natural products, such as terbutaline, fenoterol, resveratrol, and
catechin. Crystal structures of PltM in complex with phloroglucinol and FAD in different
states yield insight into substrate recognition and the FAD recycling mechanism of this
halogenase.
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alogenation is an important chemical modiﬁcation with
a potential to increase biological activity and bioavailability of molecules1,2. Moreover, halogen groups can
be further synthetically elaborated by transition metalcatalyzed coupling reactions3–5. Halogenase enzymes are attractive potential halogenating tools, because, unlike synthetic
halogenation, these enzymes ensure both regiospeciﬁcity and
green chemistry.
Flavin adenine dinucleotide (FAD)-dependent tryptophan
(Trp) halogenases have been the focus of development as halogenation tools6. Mutagenesis of Trp halogenase RebH increased
its stability, catalytic efﬁciency7, and substrate scope, to halogenate natural products and drug-like molecules8. Furthermore,
halogenation on a gram scale by this enzyme was achieved by
cross-linking it to coupled enzymes9. A recent study of the
detailed substrate proﬁle of several bacterial Trp halogenases
(including RebH) and two fungal phenolic halogenases (Rdc2 and
GsfI) indicated that Trp halogenases displayed preference
towards indole, phenylpiperidine, phenylpyrrole, and phenoxyaniline derivatives as substrates, while phenolic halogenases had
a narrow substrate proﬁle of some anilines, phenol derivatives10,
and natural products such as macrolactones and curcumin11,12.
While the substrate proﬁles of some FAD-dependent Trp halogenases appear to be quite broad10, the halide spectrum of
characterized Trp and phenolic halogenases has been limited to at
most two halides: most commonly chloride (Cl−) and bromide
(Br−) ions, and for a phenolic halogenase Bmp5, bromide (Br−)
and iodide (I−)13.
In these enzymes, the enzyme–FAD complex catalyzes
conversion of a halide ion into a highly reactive hypohalous
acid HOX, which diffuses through a protein channel protected
from solvent to the substrate binding site, where it is proposed
to react with a catalytic lysine residue to form a haloamine
adduct14–16, or to form hydrogen bonds with catalytic lysine and
glutamic acid residues to act as an active oxidant17, with subsequent halogenation of the substrate. FAD is usually a prosthetic
group that is tightly and, in some cases, covalently bound to
the enzyme, co-purifying with it18. Some FAD-dependent halogenases use FAD that can dissociate from the enzyme for
reduction (Supplementary Table 1)14,19,20. How FAD can dissociate and rebind into the conﬁnes of its binding site remains
unclear.
A bacterial halogenase PltM was originally identiﬁed as one of
three putative halogenases encoded in the biosynthetic gene
cluster of pyoluteorin, an antifungal compound containing a
dichloropyrrole moiety21. Recently, PltM was elegantly demonstrated to catalyze mono- and dichlorination of phloroglucinol
(1) (Fig. 1), yielding, instead of a biosynthetic intermediate, a
compound that serves as a potent transcriptional regulator of the
pyolyteorin biosynthesis22, whereas another halogenase, PltA,
which acted on a peptidyl carrier protein loaded pyrrole, was
shown to generate dichloropyrrole23,24. Herein, we report the
wide substrate proﬁle and the unusually large halide versatility of
PltM and its crystal structures that reveal a unique recycling
mechanism of FAD.

Results
Halide versatility of PltM. To explore the halide proﬁle of PltM,
we ﬁrst tested halogenation of 1 by PltM with NaF, NaCl, NaBr,
and NaI used individually in a reaction mixture. We identiﬁed
chlorinated, brominated, and iodinated, but not ﬂuorinated 1 as
products (Fig. 2a, Supplementary Fig. 1, Supplementary Table 2).
To our knowledge, PltM is the only example of an FADdependent halogenase that is able to use three different halides,
Cl−, Br,− and I−. We observed mono- and dihalogenation of 1
with chloride and iodide, but only mono-halogenation with
bromide; trihalogenation was never observed. We then carried
out competitive halogenation assays of 1, where two different
halides (Cl−/Br−, Cl−/I−, or Br−/I−) were present in the reaction
at equimolar ratios (Fig. 2b, Supplementary Figs. 2–4, Supplementary Table 2). Each of these reactions yielded monohalogenated products of either halogen and diiodinated 1 where
NaI was used, whereas products halogenated by two different
halides were not observed. In an attempt to obtain a heterodihalogenated product, we used compound 1 in the presence of a
10-fold molar excess of NaCl or NaBr over NaI (Fig. 2c, Supplementary Figs. 5, 6, Supplementary Table 2). For the NaCl/NaI
mixture, we identiﬁed all possible mono- and dihalogenated
products, including chloro-iodinated 1. For NaBr/NaI, we identiﬁed mono-brominated, mono-iodinated, and diiodinated 1, and
no additional products were observed. In fact, no further halogenation of the mono-brominated species was observed in any
reaction.
Substrate proﬁle of PltM. Having established the halide versatility of PltM, we next set out to investigate its substrate proﬁle.
We ﬁrst tested a set of 20 structurally diverse small molecules,
most, but not all of which were, like 1, phenolic (phenolic derivatives, anilines, nitrobenzene derivative) and included L-Trp
(Fig. 3a, Supplementary Fig. 7). All compounds were tested for
chlorination and iodination (Fig. 3b, Supplementary Figs. 8–30,
Supplementary Table 3). The products were detected and identiﬁed by liquid chromatography-mass spectrometry (LC-MS);
chlorinated products were identiﬁed by the calculated mass and
isotope ratio, and iodinated products were identiﬁed by the calculated mass, also using the corresponding chlorination reaction
as a control. PltM catalyzed halogenation of 18 of the 20 compounds tested, exhibiting remarkable substrate versatility for
phenolic compounds (Fig. 3b). The enzyme halogenated all
phenolic (1–16) and aniline (16–18) derivatives tested, while it
did not halogenate the nitrobenzene derivative 19. These data
suggest that the phenyl compounds with electron donating
groups can be accepted by PltM as substrates even when one
hydroxyl group is substituted with a moderate electron withdrawing group, such as aldehyde (12), ketone (13), and carboxylic
acid (14). On the other hand, the strongly electron withdrawing
nitro group is not tolerated. This correlation of the substrate
electron withdrawing character with halogenation activity is
consistent with other phenolic halogenases10. The halogenated
L-Trp (20) was not observed, indicating that PltM is not a Trp
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Fig. 1 Halogenation by PltM. Schematic representation of phloroglucinol (1) halogenation by PltM
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Fig. 2 Halogenation of phloroglucinol (1) by PltM. a XIC traces showing the homo-halogenation of 1 by PltM with NaCl (left), NaBr (middle), and NaI (right)
as halide sources. Blue and pink traces depict mono-halogenation and dihalogenation, respectively. b Halogenation of 1 by PltM with equimolar ratio of
NaCl/NaBr (left), NaCl/NaI (middle), and NaBr/NaI (right). Blue and green traces show mono-halogenation with smaller and larger halogens, respectively;
while purple trace indicates dehalogenation. c Halogenation of 1 by PltM with NaCl/NaI (left) and NaBr/NaI (right) in a 10:1 ratio. Blue and green traces
show mono-halogenation with smaller and larger halogens, respectively; while purple and pink traces indicate homo-dihalogenation with smaller and larger
halogens, respectively. The brown trace displays hetero-dihalogenated products. The orange trace shows the unreacted substrate 1
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Fig. 4 Crystal structures of PltM. a Full view of the structure of PltM with the conserved halogenase fold in pale yellow and the unique C-terminal region in
orange. The red loop indicates the N-terminal unconserved region after the 3rd β-sheet. The substrate binding region is shown by a box. b A zoomed in
view of the substrate binding site of the structure of PltM-compound 1 complex (yellow sticks). Residues lining the substrate binding pocket are shown as
gray sticks and the mFo–DFc polder omit map contoured at 5.5σ is shown by the gray mesh. c The FAD bound in the holoenzyme state of PltM. d The FAD
bound in a putative FAD binding intermediate state. FAD is represented as turquoise sticks in panels c and d. The ﬂexible loop that changes conformation
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halogenase, and that it is indeed a bona ﬁde phenolic halogenase.
As besides 1 the reaction with compound 11 showed very clear
signals of chlorinated and iodinated 11, we also tested compound
11 for bromination and ﬂuorination (Supplementary Fig. 19,
Supplementary Table 3). We observed mono-bromination of 11,
but not dibromination or ﬂuorination, which is consistent with
the halogenation proﬁle on the natural substrate 1. Encouraged
by the wide substrate versatility of PltM as established with
compounds 1–20, we tested its halogenase activity on four larger
molecules containing a phenolic derivative group. We tested the
FDA-approved drugs terbutaline (21) and fenoterol (22), both
short-acting β2 adrenoreceptor agonists that contain a resorcinol
moiety in their structure (Supplementary Fig. 7). Iodinated terbutaline (both mono and di) and mono-iodinated fenoterol were
obtained (Fig. 3b). We also tested the dietary natural products
resveratrol (23) and catechin (24), which were both monochlorinated and mono-iodinated by PltM. These results demonstrate that PltM can be utilized for halogenation of larger druglike molecules and natural products.
Crystal structure of PltM and its complex with phloroglucinol.
In addition to its remarkable halide versatility and a very broad
substrate proﬁle for a phenolic halogenase, PltM is at most ~15%
identical in sequence to other structurally characterized FADdependent halogenases, and it contains a unique C-terminal
region (residues 390–502) (Supplementary Fig. 31). These
4

intriguing properties prompted us to obtain a 1.80 Å-resolution
crystal structure of this enzyme (Supplementary Fig. 32, Supplementary Table 4). The crystal structure of PltM was obtained by
the single anomalous dispersion (SAD) method by using ethylmercury derivatized crystals. PltM is a monomer in solution
(Supplementary Fig. 32); the crystals of PltM contain four nearly
structurally identical monomers per asymmetric unit. A monomer of PltM (Fig. 4a) consists of a large FAD binding fold that is
conserved in FAD-dependent halogenases (residues 1–389). FAD
and halide were not found in the FAD binding site, consistent
with the lack of color of the protein and its crystals (Supplementary Fig. 32). The C-terminal quarter of the protein is a
unique helical region not found in other halogenases (Supplementary Fig. 33). The putative substrate binding cleft located in
the interface of the FAD binding fold and the C-terminal region
leads to a conserved catalytic lysine residue (Lys87), based on
structural superimposition of PltM with structures of Trp halogenases bound to L-Trp (Supplementary Fig. 33). Indeed,
mutating Lys87 to an alanine yielded a catalytically inactive
protein (Supplementary Fig. 34). The C-terminal region then
likely helps deﬁne the substrate speciﬁcity. Soaking crystals of
PltM with compound 1 yielded a strong and featureful polder
omit mFo–DFc electron density25 in three out of four substrate
binding sites in the asymmetric unit, corresponding to a molecule
of compound 1 and a water molecule that bridged it with the
protein (Fig. 4b). The binding site of compound 1 is analogous to
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that of L-Trp in the crystal structure of RebH14 and PrnA16
(Supplementary Fig. 33). The nearest carbon atom of compound
1 that can be halogenated is ~4.5 Å away from the Nε of Lys87,
further supporting the model. At its entrance, the substrate
binding cavity is lined by charged and polar side chains (Glu115,
Glu49, Lys501, and Asn405) (Fig. 4b), which would interact
favorably with hydroxyl and amino groups on PltM substrates
indicated by the activity proﬁle (Fig. 3b). One face of the phenyl
ring of 1 is in nonpolar contacts with and Pro48 and Leu111 and
the other face stacks approximately orthogonally Trp400 and
interacts with Leu401. The phenyl ring of compound 1 is stacked
nearly orthogonally against Phe90. This residue likely helps orient
the substrate for halogenation. The hydroxyl groups of bound 1
are within hydrogen bonding distances from the side chains of
Lys501, Asn405, Glu49, Ser404 and the main chain nitrogen of
Phe90 and one hydroxyl is bridged to a carbonyl oxygen of Ile499
by a water molecule. These interactions underscore the importance of the unique C-terminal region in substrate recognition.
The substrate binding site is large enough to accommodate a
diiodinated 1 (Supplementary Fig. 35). The substrate binding site
is situated relatively close to the protein surface, which could
allow access to larger substrates, like resveratrol (23). The halogenation center is nevertheless restricted by the helical C-terminal
region to addition of up to two halogens; a trihalogenated product
cannot be sterically accommodated and neither can halogenated
L-Trp (Supplementary Fig. 33).
Crystal structures of PltM with FAD bound in different states.
PltM represents a type of FAD-dependent enzymes, where FAD
dissociates out of its binding site for reduction. To gain structural
insight into this enigmatic process, we sought to determine a
crystal structure of PltM–FAD complex by soaking the crystals of
apo PltM with FAD. We obtained two different crystal forms of
PltM–FAD complexes, where a molecule of FAD was bound to
PltM in two different states (Fig. 4c, d, Supplementary Table 4).
In one state, an FAD molecule was bound at a site and orientation
analogous to those observed in structures of other FADdependent halogenases, where the isoalloxazine group of the
FAD was fully encased by the enzyme (Fig. 4c, Supplementary
Fig. 36). A chloride ion was well resolved at a conserved site near
the FAD. In the other state, the FAD molecule was bound near
the mouth of the FAD binding cleft, with the clearly resolved
isoalloxazine ring in the same plane, but oriented perpendicularly
to the fully bound state, also making extensive contacts with the
protein (Fig. 4d). The electron density for the rest of the FAD
molecule is not observed due to disorder (Supplementary Fig. 37),
as in this state the adenine nucleotide moiety is directed into the
solvent. This structure may represent an intermediate between
the apo and the fully bound FAD state. The crystals of PltM–FAD
complexes in this state belong to the same crystal form as the
crystals of all other complexes in this study; therefore, crystal
packing interactions have no effect on the FAD binding state. A
short nonconserved loop containing three Ala, a Gly and a Ser
(residues 172–178) and the side chain of Gln321 are in two different conformations in these two structures (Fig. 4c, d). In the
holoenzyme state, the loop and Gln321 form one side of the
narrow cleft holding the adenine nucleotide portion of FAD in
place: the side chain of Ala173 interacts with the adenine ring of
the FAD, Ala174 interacts with the phosphosugar bridge, and the
aliphatic portion of Gln321 holds the riboﬂavin bridge. In the
state with partially bound FAD, this cleft is collapsed, and ﬁlled
with water. In this state, the isoalloxazine ring is sandwiched
between Phe325 and the backbone of loop residues Ala174 and
Gln175, including the Cβ of the latter residue. The FAD binding
pocket does not contain a Cl−, indicating that a halide ion binds

ARTICLE

upon the ﬁnal steps of FAD binding. Previous kinetic experiments
with RebH26 and p-hydroxybenzoate hydroxylase27 suggested
that kinetically signiﬁcant conformational changes involving FAD
dynamics occurred in FAD recycling. For both enzymes, it was
proposed that a distinct mechanistically important state exists
where the ﬂavin ring of FAD can undergo redox chemistry, while
being sufﬁciently shielded away from the solvent. This structure
may represent such intermediate; future extensive kinetic studies
probing the FAD recycling mechanism are needed to address this
directly.
Halogenation assays in fermentation culture. As a preliminary
assessment of potential use of PltM in a fermentation setting, we
tested whether phloroglucinol (1) can be halogenated upon
adding it to the culture of Escherichia coli BL21(DE3) overexpressing PltM. We also validated the substrate binding cavity
observed in the crystal structures by testing halogenation by two
point mutants of PltM, L111Y and S404Y, in this setting. These
two residues (one from the FAD binding fold and one from the
C-terminal region) line the substrate binding cavity, and their
bulkier substitutions are predicted to block binding of 1 (Supplementary Fig. 38). In addition, as negative controls, we used
PltM K87A that was demonstrated to be inactive in vitro as well
as PltA. All ﬁve proteins were expressed at the same level. The
cells expressing wild-type PltM generated mono- and dichlorinated 1 (Fig. 5, Supplementary Fig. 39). No halogenated product
was observed in cultures expressing PltM K87A and PltA, validating the PltM as the sole source of halogenation activity. For the
cells expressing L111Y and S404Y mutants, the product yield was
signiﬁcantly reduced compared to wild-type; the effect of the
S404Y mutation was especially severe. We determined a crystal
structure of PltM L111Y, which showed that the overall protein
structure is unperturbed and the only effect of the mutation was
to obstruct the access to the substrate binding pocket, as predicted
(Supplementary Fig. 38). S404Y caused a more drastic effect than
L111Y because Y404 was predicted to sterically clash with the
bound substrate. These data further validated the structure-based
deﬁnitions of the substrate binding site and suggested a potential
for halogenation in a fermentation setting. Future fermentation
experiments to maximize the yield of halogenated product will
require optimization of the producing host strain and other
culture growth conditions.
Kinetics and regiospeciﬁcity of PltM in optimized reactions.
For quantitative analysis of enzyme kinetics and detailed structural characterization of reaction products, as well as for potential
future biotechnological use, we extensively optimized in vitro
enzymatic reaction conditions and coupled enzymes to maximize
product yield. The critical factors of the optimized conditions
were introducing glucose dehydrogenase (GDH) for NADPH
regeneration28 and lowering the concentrations of NADPH and
halide salts. This optimization signiﬁcantly improved reaction
yields, resulting in full conversion of several substrates (Supplementary Table 7). This additional information corroborated the
preference for substrates containing electron withdrawing groups
and showed preference of PltM for substrates with 1- and 3hydroxyl or amino groups. We determined the halide preference
and evaluated quantitatively the kinetics of chlorination and
bromination of substrates 3, 11, and 16, which showed 100%
conversion upon overnight reaction (Table 1 and Supplementary
Fig. 40). Kinetic of iodination could not be analyzed quantitatively due to gradual enzyme precipitation in the presence of
iodide. These data indicated that PltM preferred chlorination for
all substrates that were eventually dichlorinated. The preference
for bromination versus iodination depended on particular
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Table 1 Kinetic parameters for halogenations of selected substrates
Substrate
3

Halogen
Cl
Br

11

Cl

16

Br
Cl

Br

Substrate/product
3/Cl-3
Cl-3/diCl-3
3/Br-3
Br-3/diBr-3
11/Cl-11
Cl-11/diCl-11
11/Br-11
16/Cl-16ab
16/Cl-16b
Cl-16a/diCl-16
Cl-16b/diCl-16
16/Br-16a
16/Br-16b
Br-16a/diBr-16
Br-16b/diBr-16

kcat (min−1)
2.3 ± 0.1a
0.40 ± 0.01
1.9 ± 0.1
0.38 ± 0.01
1.6 ± 0.1
0.18 ± 0.01
0.24 ± 0.02
0.35 ± 0.01
0.22 ± 0.01
0.95 ± 0.01
1.0 ± 0.1
0.47 ± 0.04
2.2 ± 0.1
0.21 ± 0.02
2.0 ± 0.1

Km (μM)
(7.6 ± 1.3) × 10−2
0.11 ± 0.02
0.71 ± 0.2
0.78 ± 0.17
8.4 ± 0.4
0.44 ± 0.02
(1.1 ± 0.2) × 103
1.1 ± 0.3
1.1 ± 0.3
18 ± 5
15 ± 9
151 ± 20
151 ± 20
6.0 ± 1.2
(1.3 ± 0.1) × 103

kcat/Km (min−1 μM−1)
30 ± 5
3.5 ± 0.6
2.7 ± 0.6
0.49 ± 0.11
0.19 ± 0.01
0.41 ± 0.02
(2.2 ± 0.2) × 10−4
0.31 ± 0.09
0.19 ± 0.06
(5.2 ± 1.4) × 10−2
(7.0 ± 4.4) × 10−2
(3.1 ± 0.5) × 10−3
(1.5 ± 0.2) × 10−2
(3.5 ± 0.8) × 10−2
(1.5 ± 0.2) × 10−3

aThe values of all mono-halogenation and dihalogenation rate constants k
cat,1 and kcat,2, respectively, and Km for mono-halogenation and dihalogenation (deﬁned as (kd,1 + kcat,1)/ka,1 and (kd,2 + kcat,2)/ka,2,
respectively) were determined by nonlinear regression using DynaFit, as described in Methods
bTwo distinct mono-halogenation products of the same reaction are denoted by labels a and b

substrates, with 3 and 16 showing preference for bromination,
and 11 for iodination. In fact, both 3 and 16 were dibrominated
by PltM. Chlorination and bromination of 3 and 16 occurred
with similar efﬁciencies, whereas 11 was chlorinated much better
than brominated or iodinated. Interestingly, two monohalogenated products were observed for iodination of 11 and
for halogenation of 16. No ﬂuorination was still observed for any
substrates at the optimized conditions.
The high yield of chlorination and bromination of these and
several other compounds allowed us to establish the regiospeciﬁcity of the halogenation by PltM. However, some substrates or
products were insufﬁciently stable during halogenation reactions
6

precluding their quantitative structural analysis. We determined
the structures of the ﬁnal dichlorinated products of 3, 8, 9, 11, 15,
16, 18, as well as the monochlorinated product of 23 and the
dibrominated product of 3 by NMR spectroscopy. The resulting
products were 4,6-diCl-3, 4,6-diCl-8, 2,4-diCl-9, 2,6-diCl-11, 3,5diCl-15, 4,6-diCl-16, 4,6-diCl-18, 4-Cl-23, and 4,6-diBr-3,
respectively (Fig. 6 and Supplementary Figs. 42–59). These
structures were consistent with the time course experiments
showing one mono-halogenated intermediate for symmetrical
substrates 3 and 11 and two mono-halogenated intermediates for
asymmetrical substrate 16. Likewise, for most other substrates
(8, 15, and 18) the structures of the respective monochlorinated
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Fig. 6 Structures of the products of halogenation by PltM. Structures, as
determined by NMR spectroscopy, of products resulting from the
halogenation of compounds 3, 8, 9, 11, 15, 16, 18, and 23 by PltM

b

50

OH

CI-23
OH

intermediates are unambiguously inferred owing to the product
symmetry. These results show that for mono- or di-hydroxylated
or aminated substrates, PltM halogenates almost exclusively in
ortho to these polar groups, but not between them. However,
when a methyl or a styrene moiety was found in meta to two
hydroxyls, as in compound 9 (which was dichlorinated) and
resveratrol (23; which was monochlorinated), respectively, we
observed that a chlorination event occurred between the two
hydroxyls.

HO

23

Affi-Gel® reaction

Development of an immobilized halogenating system. The
halogenation yield is limited by the stability of proteins, with
PltM being the limiting factor. To achieve a more efﬁcient and
scalable halogenation reaction, we developed a method, where all
three proteins were immobilized on agarose resin (Afﬁ-Gel® 15),
packed into a spin column and then used as a resin conjugate for
halogenation. The halogenation reactions were performed by
adding substrate and reagents into the column. This proteinbound resin showed a high halogenation yield for some compounds, which could not be efﬁciently halogenated by free
enzymes in solution (Fig. 7). Notably, the enzyme–resin conjugate
could be reused 5–6 times without signiﬁcant loss of efﬁciency
(Supplementary Fig. 41).
The remarkable halide versatility for any FAD-dependent
halogenase and very broad substrate proﬁle for a phenolic
halogenase call for future exploration of PltM as a halogenation
tool. Our structures revealed a unique architecture of this enzyme,
and an FAD orientation that may be relevant to the FAD
recycling mechanism shared by FAD binding enzymes.
Methods
Materials and instrumentation. The PltM, SsuE, and PltA (used as a control in
this study) proteins were overexpressed and puriﬁed based on our previously
described protocols23,24. DNA primers for PCR were purchased from Integrated
DNA Technologies (IDT; Coralville, IA, USA). Restriction enzymes, Phusion DNA
polymerase, and T4 DNA ligase were purchased from New England BioLabs (NEB;
Ipswich, MA, USA). All chemicals and buffer components were purchased from
Sigma-Aldrich or VWR (Radnor, PA, USA) and used without any further puriﬁcation. Size-exclusion chromatography was performed on a fast protein liquid
chromatography (FPLC) system BioLogic DuoFlow (Bio-Rad; Hercules, CA, USA)
by using a HiPrep 26/60 S-200 HR column (GE Healthcare, Piscataway, NJ, USA).
LC-MS was performed on a Shimadzu high-performance liquid chromatography
(HPLC) system equipped with a DGU-20A/3R degasser, LC-20AD binary pumps, a
CBM-20A controller, a SIL-20A/HT autosampler (Shimadzu, Kyoto, Japan), and
Vydac HPLC DENALI™ Column (C18, 250 × 4.6 mm, 5 μm particle size) from
Grace (Columbia, MD, USA) and an AB SCIEX TripleTOF 5600 (AB SCIEX,

CI-23
Optimized in vitro reaction
Control

40

45
Time (min)

50

Fig. 7 HPLC chromatograms of chlorination reactions by PltM with
substrates. Reaction with a 12 and b 23 prior (black traces) and after
optimization employing Afﬁ-Gel® resin (pink traces)

Redwood City, CA) mass spectrometer recording in negative or positive mode
between 80 and 600 m/z. HPLC was performed on an Agilent Technologies
1260 Inﬁnity system equipped with a Vydac HPLC DENALI™ column (C18,
250 × 4.6 mm, 5 μm particle size) and an Alltech Econosil HPLC column (C18,
250 × 10 mm, 10 μm particle size; Grace) for analytical and semi-preparative
experiments, respectively. 1H and 13C NMR spectra were recorded at 400 and 500
(for 1H) as well as 100 MHz (for 13C) on Varian 400 and 500 MHz spectrometers,
using deuterated solvents as speciﬁed. Chemical shifts (δ) are given in parts per
million (ppm). Coupling constants (J) are given in Hertz (Hz), and conventional
abbreviations used for signal shape are as follows: s, singlet; d, doublet; t, triplet; m,
multiplet; q, quartet.
Synthesis of compound 15. Aluminum chloride (1.3 g, 9.99 mmol) was slowly
added to a solution of phloroglucinol (1, 315 mg, 2.50 mmol) in 1:1/1,2-dichloroethane:nitrobenzene (10 mL) at 0 °C. After stirring this mixture at this temperature for 10 min under a nitrogen atmosphere, acetyl chloride (0.21 mL, 3.00 mmol)
was added. Then the ice bath was removed, and the mixture was stirred at 80 °C for
2 h. The reaction progress was monitored by TLC (1:2/EtOAc:Hexanes, Rf 0.35).
The reaction mixture was quenched with H2O (60 mL), extracted with EtOAc (2 ×
100 mL), washed with brine (20 mL), and then dried over MgSO4. The organic
layer was removed under reduced pressure and the residue was puriﬁed by ﬂash
column chromatography (SiO2, 1:2/EtOAc:Hexanes) to afford the known compound 1530 (223 mg, 53%) as a yellow solid: 1H NMR (400 MHz, CD3OD) δ 5.78
(s, 2H), 2.58 (s, 3H); 13C NMR (100 MHz, (CD3)2SO) δ 203.1, 164.9, 164.5, 104.2,
94.1, 31.3.
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PltM mutagenesis. PltM mutants K87A, L111Y, and S404Y were constructed by
splicing-by-overlap-extension method31. The sequences downstream and upstream
of the mutation site were ampliﬁed ﬁrst individually from ppltM-pET28a(NHis).
For PltM K87A mutant; the primer pairs were #1: 5′-CGCCTGCGGGATCgcgCT
GGGCTTCAGTTTTG-3′ with #2: 5′-CATACTCGAGCTAGACTTTGAGGATGA
AACGATTG-3′ and #3: 5′-CAAAACTGAAGCCCAGcgcGATCCCGCAGGCG-3′
with #4: 5′-GCAGCTCTCATATGAATCAGTACGACGTCATTATC-3′. For PltM
L111Y mutant; the primers were #5: 5′-CTTGTGGCCCCGCCGtatAAGGTGCCG
GAAGCC-3′ with #2 and #6: 5′-GGCTTCCGGCACCTTataCGGCGGGGCCACA
AG-3′ with #4. For PltM S404Y mutant, the primer pairs were #7: 5′-CTGGCTC
AGCGGCtatAACCTGGGCAGTGC-3′ with #2 and #8: 5′-GCACTGCCCAGGTTataGCCGCTGAGCCAG-3′ with #4. The PCR products of the above primer pairs
were used as templates for another round of PCR using primers #2 and #4. The
products from the second round of PCR were digested with restriction enzymes
NdeI and XhoI and ligated into NdeI/XhoI-linearized pET28a, yielding
ppltMK87A-pET28a, ppltML111Y-pET28a, and ppltMS404Y-pET28a. The mutations were veriﬁed by DNA sequencing (Euroﬁns Genomics).
Preparation of pgdh-pET28a overexpression construct. The glucose dehydrogenase (gdh) gene was ampliﬁed from genomic DNA of Bacillus subtilis subsp.
subtilis 168 by PCR with the forward and reverse primers: 5′-AGGATGCATATG
TATCCGGATTTAAAAGGAAAAG-3′ and 5′-CGCTTTCTCGAGTTAACCGCG
GCCTGCCTGGAAT-3′, respectively. The PCR product was puriﬁed by agarose
gel extraction and digested by restriction enzymes NdeI and XhoI, which was
subsequently ligated into NdeI/XhoI-linearized pET28a. The resulting plasmid
pgdh-pET28a was transformed into a chemically competent E. coli TOP10 strain,
and the cloning was veriﬁed by sequencing of the puriﬁed plasmids.
Preparation of PltM and coupled enzymes for in vitro assays. Open reading
frames encoding PltM and FAD reductase SsuE were cloned into E. coli expression
vectors as previously reported23. For the production of PltM, SsuE, and GDH, the
expression vectors were transformed into E. coli BL21(DE3) (ATCC; Manassas,
VA). In each case, a colony was grown overnight at 37 °C with shaking at 200 rpm
in LB medium (5 mL) supplemented with 50 μg/mL kanamycin. These overnight
cultures were inoculated into LB medium (1 L) supplemented with 50 μg/mL
kanamycin. Cultures were grown (37 °C, 200 rpm) until an attenuance at 600 nm of
0.6 was reached. At this time, protein expression was induced by adding isopropylβ-D-1-thiogalactopyranoside (IPTG, 0.2 mM), and the cultures were incubated at
16 °C with shaking at 200 rpm for an additional 20 h. The cells were harvested by
centrifugation at 3000×g for 10 min at 4 °C. The cell pellets were washed with
buffer A (50 mM sodium phosphate pH 7.4, 400 mM NaCl, 5 mM imidazole, and
10% glycerol). The cells were resuspended in 40 mL of buffer A supplemented with
1 mM dithiothreitol (DTT) and 1 mM phenylmethanesulfonyl ﬂuoride (PMSF).
The cells were then lysed by intermittent sonication, followed by clariﬁcation by
centrifugation at 40,000×g for 45 min at 4 °C. The supernatants were incubated
with 0.5 mL of pre-washed NiII-NTA agarose resin (Qiagen, Valencia, CA) at 4 °C
for 2 h with slow tumbling. The slurry was loaded onto a column and washed with
2 × 5 mL of buffer A followed by elution with a gradient of imidazole concentration
in buffer A (2 × 5 mL of 20 mM, 5 mL of 40 mM, 5 mL of 60 mM, 2 × 5 mL of 250
mM). Fractions containing pure proteins were combined and dialyzed against 3 ×
2 L of buffer B (50 mM sodium phosphate pH 7.4, 2 mM β-mercaptoethanol
(βME), and 10% glycerol). Each of the three dialysis steps was performed at least
for 4 h. The dialyzed proteins were concentrated to ~20 mg/mL for PltM and GDH
or ~2.5 mg/mL for SsuE by using Amicon Ultra-15 Centrifugal Filter Units (EMD
Millipore, Billerica, MA, USA) with 10-kDa molecular weight cutoff (MWCO) for
PltM and GDH or 3-kDa MWCO for SsuE, and protein concentrations were
determined by absorbance at 280 nm with calculated extinction coefﬁcients ε =
59,840, 20,340, and 29,910 M−1 cm−1 for PltM, SsuE, and GDH, respectively
(http://protcalc.sourceforge.net/cgi-bin/protcalc). The total yields of pure PltM,
SsuE, and GDH were 17.6, 6.0, and 10.3 mg from 1 L of culture, respectively. The
proteins were ﬂash frozen in liquid nitrogen and stored at −80 °C for biochemical
assays. The point mutants of PltM were puriﬁed by using the above protocol for the
full-length PltM.
Preparation of PltM for crystallography. Wild-type PltM and PltM L111Y
mutant were puriﬁed as described above with an additional size-exclusion chromatography step. Wild-type PltM and PltM L111Y eluted from NiII resin were
loaded onto an S-200 column equilibrated in 40 mM Tris–HCl, pH 8.0, 100 mM
NaCl, 2 mM βME. Fractions containing NHis6-PltM were pooled and concentrated
to 40 mg/mL by using an Amicon Ultra-15 Centrifugal Filter Unit with 10 kDa
MWCO. Puriﬁed PltM proteins were kept on ice for crystallization studies.
In vitro assays of PltM with various substrates and halides. The halogenation
assays were carried out similarly to a recently described procedure22. The substrates
that have been tested are given in Fig. 3a and Supplementary Fig. 7.
For substrate proﬁle determination (Assay 1), 100 μL reactions were carried out
in 30 mM sodium phosphate pH 7.4. As a halide source, we used 200 mM of either
NaF (Assay 1a), NaCl (Assay 1b), NaBr (Assay 1c), or NaI (Assay 1d). To ensure
that PltM is incapable of ﬂuorinating, an additional 200 μL reaction with 300 mM
8

NaF was run. We also ran 200 μL reaction with 400 mM NaBr to ensure no
additional bromination reaction occurred. Each reaction also contained a speciﬁed
substrate (0.5 mM), FAD (0.2 mM), NADPH (5 mM), PltM (5.5 μM), and SsuE
(5.0 μM). The reactions were initiated by adding NADPH under N2. The reaction
tubes were tightly closed to avoid contact with air. The reaction mixtures were
incubated at 25 °C for 3 h prior to extraction with EtOAc (4 × 100 μL). The organic
layer was dried by a gentle ﬂow of air, and the residue was dissolved in MeOH to
prepare 1–10 μg/mL samples for LC-MS analysis.
To establish if hetero-dihalogenation by PltM could be observed, halogenating
competition assays in 1:1 or 10:1 mixture of two different halide salts were
performed (Assay 2). The reactions contained the same components as above
except single halide salts were replaced with either a 1:1/NaCl:NaBr (Assay 2a),
1:1/NaCl:NaI (Assay 2b), or 1:1/NaBr:NaI (Assay 2c) mixtures (100 mM of each
halide). The reactions were initiated by adding NADPH under N2. A 1:1/NaCl:
NaBr reaction was also performed with 200 mM of each halide to test the
occurrence of homo-di- or hetero-chlorination/bromination, and 10:1/NaCl:NaI
(Assay 2d) and 10:1/NaBr:NaI (Assay 2e) mixtures with 200 mM of NaCl or NaBr
and 20 mM of NaI were tested to check whether chlorination or bromination could
occur in the presence of iodide and whether iodination can occur with chlorination
or bromination to yield a Cl,I-substrate or Br,I-substrate. The reactions were
incubated and processed as described above in Assay 1.
Optimized in vitro PltM halogenation assay. To increase the production of
halogenated molecules and decrease the amount of NADPH required, the above
in vitro assay was optimized by using an additional enzyme, GDH28. The optimized reaction mixture contained substrate (0.5 mM for chlorination and bromination; 0.25 mM for iodination; prepared from 50 mM stock in DMSO), FAD (5
μM), NADPH (5 μM), PltM (6 μM), SsuE (5 μM), GDH (0.5 μM), glucose (20
mM), NaX (10 mM for chlorination and bromination; 0.5 mM for iodination), and
sodium phosphate (30 mM, pH 7.4), and was incubated at room temperature. The
overall yield of halogenation products was determined for reactions run overnight
for several substrates (Supplementary Table 7). Conversion of the substrate to
halogenated products was monitored by HPLC at λ = 275–320 nm, where the
absorbance of molecules is not affected by halogenation, and quantiﬁed as fraction
of reaction species (%). The time course experiments for kinetic analysis were
performed in 100 μL reaction mixtures by quenching the reactions at 0, 5, 15, 30,
60, 120, 240, and 360 min (for 3 and 16), and an additional 720 min (for 11) for
chlorination and bromination, and at 0, 30, 60, 120, 240, and 480 min (for 3 and
16), or an additional 720 min (for 11) for iodination. The time course experiments
were performed in duplicate. Compound 1 was unstable under these optimized
conditions, and it was not tested. The in vitro analysis of K87A mutant was
performed overnight in 100 μL reaction mixture by using compound 11 as a
substrate. Wild-type PltM was used as a positive control, and no enzyme reaction
was used as a negative control. In all the above reactions, the compounds were
extracted with EtOAc (4 × 100 μL) and dried under gentle air ﬂow. The products
were dissolved in MeOH (30 μL for chlorination and bromination; 15 μL for
iodination) for HPLC analysis. The scale-up experiments were performed overnight in 25 mL for compound 23, in 50 mL for compounds 3, 8, 9, 11, 15, and 18,
or 100 mL for 16. PltM concentration was 25 μM with compounds 15 and 250 μM
with compound 23. To process the chlorination reaction of compound 23, ice-cold
MeOH (50 mL) was added to precipitate the proteins. This mixture was incubated
for 2 h at −20 °C, and the protein precipitate was removed by centrifugation
(40,000×g, 30 min, 4 °C). The pellet was washed by ice-cold MeOH (50 mL) and
centrifuged down again (40,000×g, 15 min, 4 °C). The supernatant was combined in
a round-bottomed ﬂask, and MeOH was removed in vacuo. The products were
extracted with EtOAc (4 × reaction volume) and dried in vacuo. These were dissolved in MeOH (0.5–1 mL) for puriﬁcation by semi-preparative HPLC.
Halogenation assay using immobilized enzymes. To increase the yield of
halogenation reaction and make the enzymes reusable, PltM, SsuE, and GDH, we
immobilized these proteins on Afﬁ-Gel® 15 resin (Bio-Rad, Hercules, CA). To
increase the stability of the coupled enzymes, GDH from Bacillus amyloliquefaciens
SB5 (GDH-BA)32 was used in this assay. This enzyme was expressed and puriﬁed,
as described above, from a pET23a vector (ampR) containing a synthetic gene
encoding this enzyme (NCBI accession #JQ305165) with an NHis6 tag, purchased
from GenScript (Piscataway, NJ). The enzymes were dialyzed into buffer C, which
contains HEPES (50 mM, pH 7.5), βME (2 mM), and glycerol (10%). Suspended
Afﬁ-Gel® resin (250 μL) was transferred into a QIAquick spin column (Qiagen),
and the resin was washed three times with 500 μL of H2O and buffer D (30 mM
HEPES, pH 7.5). For each time, the wash solution was removed by centrifugation
(400×g, for 15–30 s, 4 °C). The washed resin was incubated with SsuE (~50 μM,
300 μL) for 4 h at 4 °C. The beads were washed with buffer D twice and subsequently incubated with a mixture of GDH-BA (~200 μM, 50 μL) and PltM (~500
μM, 250 μL) overnight at 4 °C. This resin–enzyme conjugate was washed twice with
buffer D and preserved in 4 °C in buffer D until needed. For each 250 μL resin, 300
μL of reaction solution, which contained substrate (0.5 mM), FAD (5 μM), NADPH
(5 μM), glucose (20 mM), NaCl (10 mM), and HEPES (30 mM, pH 7.5), was used.
The reaction with resveratrol (23) was performed overnight at room temperature.
The reaction solution was collected by centrifugation (400 × g, every 15–30 s until
the solution was removed, 4 °C), and the resin–enzyme conjugate in the column
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was washed with buffer D (300 μL) three times. These solutions were extracted with
EtOAc (4 × 300 μL) and dried in vacuo. The solid material was dissolved in MeOH
(200 μL) and analyzed by HPLC (Fig. 7). The reusability of the resin–enzyme
conjugate was tested with substrates 3 and 11 (Supplementary Fig. 41). The
reactions (same as above) were run for 1 h at room temperature and processed as
described above. After processing the reaction, the same reaction was repeated four
more times. After the 5th reaction, the beads were stored at 4 °C overnight in buffer
D. The 6th–10th reactions were performed in the following day.
Kinetic analysis of PltM halogenation. To determine the halogenation preference, the kinetic parameters were obtained by the global nonlinear regression
analysis of all reaction species using DynaFit software29 for the following halogenation mechanism:
ka;1
EþS $ ES
kd;1
kcat;1

ð1Þ

E  S ! E  P1

ð2Þ

ka;2
EP1 þ S $ EP1  S
kd;2

ð3Þ

kcat;2

ð4Þ

EP1  S ! E þ P2

where E, S, P1, and P2 are enzyme, substrate, mono-, and dihalogenated product,
respectively.
Cell-based activity assay of PltM. E. coli BL21(DE3) cells were transformed with
ppltM-pET28a, ppltMK87A-pET28a, ppltML111Y-pET28a, ppltMS404Y-pET28a,
and ppltA-pET28a. The ppltA-pET28a plasmid overexpressing the halogenase PltA
whose substrate is pyrrolyl-S-PltL (a peptidyl carrier protein-linked pyrrole) was
used as a negative control23. Five colonies from each transformant were cultured in
2 × 500 mL of LB medium (for ppltM-pET28a, ppltML111Y-pET28a, and
ppltMS404Y-pET28a) and 1 × 500 mL of LB medium (for ppltMK87A-pET28a and
ppltA-pET28a) with 50 μg/mL kanamycin at 37 °C and 200 rpm until attenuance of
0.2 at 600 nm. The cultures were then moved to 25 °C until attenuance of 0.5.
Protein expression was induced by adding 0.2 mM IPTG to all seven ﬂasks, and the
cultures were incubated with shaking for 1 h. 12.5 μg/mL of compound 1 was
added to 1 × 500 mL of LB medium containing ppltM-pET28a, ppltMK87ApET28a, ppltML111Y-pET28a, ppltMS404Y-pET28a, and ppltA-pET28a. Compound 1 was not added to the three remaining ﬂasks (negative controls). After
additional incubation for 20 h, the cells were pelleted at 5000×g for 10 min, and the
supernatant was collected. The supernatant was extracted with EtOAc (3 × 330
mL), which was dried in vacuo. This was then dissolved in MeOH (100 μL) prior to
addition of H2O (800 μL) followed by centrifugation at 20,000×g for 10 min to
remove the precipitate. The supernatant was collected and 1 μL was diluted into
199 μL of MeOH for LC-MS analysis (Supplementary Table 6).
HPLC and LC-MS analysis of halogenated products. The halogenation reaction
products were analyzed by HPLC or LC-MS by injecting 10 μL of each sample. The
compounds were separated by reversed-phase HPLC at the ﬂow rate of 0.2 mL/min
by using the following program: eluent A = H2O; eluent B = MeCN; gradient = 2%
B for 5 min, increase to 100% B over a 30 min period, stay at 100% B for 9 min,
decrease to 2% B over a 1 min period, and re-equilibrate the column at 2% B for 30
min. For HPLC analysis, the molecules were observed by absorbance at λ = 275 nm
as described above. As necessary, the following mass spectrometer was operated in
negative and positive modes with the following parameters: for negative mode,
mass range, 80–600 m/z in proﬁle mode; temperature, 550 °C and ion spray voltage
ﬂoating, −4500 V, and for positive mode, mass range, 80–600 m/z in proﬁle mode;
temperature, 550 °C and ion spray voltage ﬂoating, 4500 V. The presence of each
compound was analyzed by extracted ion chromatograph (XIC) with the expected
mass ±0.05 Da for Assay 1 and Assay 2 and ±0.005 Da for Assay 3 (Fig. 2a–c,
Supplementary Figs. 1–6 and 10–30, and Supplementary Tables 2, 3, and 6). The
LC-MS was operated by Analyst TF Software (SCIEX, Framingham, MA), and the
data was analyzed by PeakView (SCIEX). To purify 4 selected scaled-up halogenated products, semi-preparative HPLC was performed by injecting 100 μL per
injection at 1 mL/min by using the following gradient program with eluent A as
H2O (with 0.1% TFA) (for compounds 3 and 11) or 10 mM ammonium bicarbonate (for 16) and eluent B as MeCN: 2% B for 10 min, increase to 100% B over a
40 min period, stay at 100% B for 5 min, decrease to 2% B over a 1 min period,
followed by re-equilibration in 2% B for 9 min. The collected peak fractions were
dried under reduced pressure and lyophilized for NMR analysis.
NMR analysis of products of large-scale halogenation. The exact position for
the various halogenations was determined either by comparison with commercially
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available standards (4,6-dichlororesorcinol) or by a combination of HMBC and
HSQC experiments.
The analysis of halogenation products is presented as follows.
Analysis of 4,6-dichlororesorcinol (4,6-diCl-3): 1H NMR (500 MHz, CD3OD,
Supplementary Fig. 42) δ 7.17 (s, 1H), 6.52 (s, 1H).
Analysis of 4,6-dibromoresorcinol (4,6-diBr-3): 1H NMR (500 MHz, CD3OD,
Supplementary Fig. 43) δ 7.45 (s, 1H), 6.53 (s, 1H); 13C NMR (100 MHz, CD3OD,
Supplementary Fig. 44) δ 154.1, 134.8, 103.5, 99.3.
Analysis of 2,4,6-trichlororesorcinol (4,6-diCl-8): 1H NMR (500 MHz, CD3OD,
Supplementary Fig. 45) δ 7.23 (s, 1H).
Analysis of 2,4-dichloro-5-methylresorcinol (2,4-diCl-9): 1H NMR (500 MHz,
CD3OD, Supplementary Fig. 46) δ 6.43 (q, J = 0.5 Hz, 1H), 2.39 (d, J = 0.5 Hz, 3H);
13C NMR (100 MHz, CD OD, Supplementary Fig. 47) δ 151.9, 134.6, 112.0, 110.0,
3
101.3, 16.5.
Analysis of 2,6-dichloro-3,5-dihydroxybenzyl alcohol (2,6-diCl-11): 1H NMR
(500 MHz, CD3OD, Supplementary Fig. 48) δ 6.55 (s, 1H), 4.85 (s, 2H); 13C NMR
(100 MHz, CD3OD, Supplementary Fig. 49) δ 152.3, 136.2, 112.8, 103.4, 58.9. The
HMBC for 2,6-dichloro-3,5-dihydroxybenzyl alcohol is presented in
Supplementary Fig. 50.
Analysis of 3,5-dichloro-2,4,6-trihydroxyacetophenone (3,5-diCl-15): 1H NMR
(500 MHz, CD3OD, Supplementary Fig. 51) δ 2.69 (s, 3H).
Analysis of 5-amino-2,4-dichlorophenol (2,4-diCl-16): 1H NMR (400 MHz,
CD3OD, Supplementary Fig. 52) δ 7.06 (s, 1H), 6.38 (s, 1H); 13C NMR (100 MHz,
CD3OD, Supplementary Fig. 53) δ 152.4, 143.8, 128.7, 109.4, 108.7, 102.8. The
HSQC and HMBC for 5-amino-2,4-dichlorophenol are presented in
Supplementary Figs. 54 and 55, respectively.
Analysis of 2,4-dichloro-1,5-diaminobenzene (2,4-diCl-18): 1H NMR (500
MHz, CD3OD, Supplementary Fig. 56) δ 7.04 (s, 2H); 13C NMR (100 MHz,
CD3OD, Supplementary Fig. 57) δ 142.8, 128.3, 128.2, 108.5.
Analysis of 4-chloro-resveratrol (4-Cl-23): 1H NMR (400 MHz, CD3OD,
Supplementary Fig. 58) δ 7.33 (d, J = 8.6 Hz, 2H), 6.93 (d, J = 16.2 Hz, 1H), 6.75 (d,
J = 16.2 Hz, 1H), 6.74 (d, J = 8.6 Hz, 2H), 6.57 (br s, 2H).
Analysis of resveratrol (23): 1H NMR (400 MHz, CD3OD, Supplementary
Fig. 59) δ 7.33 (d, J = 8.6 Hz, 2H), 6.93 (d, J = 16.2 Hz, 1H), 6.77 (d, J = 16.6 Hz,
1H), 6.74 (d, J = 8.6 Hz, 2H), 6.42 (d, J = 2.2 Hz, 2H), 6.13 (t, J = 2.2 Hz, 1H).
Crystallization of PltM. PltM crystals were obtained by the hanging drop method
with drops containing 0.5 μL of PltM (40 mg/mL) and 0.5 μL of the reservoir
solution (0.1 M Tris, pH 8, 0.2 M NaCl, 0.1 M CaCl2 and 12–17% PEG 8000). The
drops were equilibrated against 0.5 mL of reservoir solution at 21 °C. Long rodshaped crystals appeared after 1–3 days. The crystals were cryoprotected by a
gradual transfer to the solution with the same composition as the reservoir solution, additionally containing 20% glycerol. The crystals were then frozen by a rapid
immersion into liquid nitrogen.
Determination of the crystal structure of PltM. PltM does not contain a sufﬁcient number of Met residues for structure determination by using anomalous
signal from selenium atoms in Se-Met PltM. However, PltM contains eight Cys
residues, which, if accessible, would react with Hg salts. Hg derivative crystals of
PltM were prepared by transferring native crystals from its mother liquor to the
reservoir solution containing 1 mM ethyl mercury phosphate (EMP) and incubated
overnight. These crystals were cryoprotected similarly to the native crystals. X-ray
diffraction data for this and other crystals of PltM were collected at 100 K at the
wavelength of 1 Å at synchrotron beamline 22-ID at the Advanced Photon Source
at the Argonne National Laboratory (Argonne, IL). All datasets were indexed,
integrated and scaled using HKL200033. The structure was determined by the SAD
method from the EMP derivative data set (using the wavelength of 1.0 Å), as
follows. A heavy atom search by using direct method-based SHELXD program34
initially yielded a substructure of 22 Hg atoms in the asymmetric unit. This Hg
substructure was used as an input in Autosolve in PHENIX suite to obtain initial
phases35, which were bootstrapped by difference Fourier analysis to yield the total
of 33 Hg atoms and a readily interpretable electron density map, with the ﬁgure of
merit of 0.71 after density modiﬁcation. The structure of the Hg-derivatized PltM
was then iteratively built by using COOT36 and reﬁned by using REFMAC537
(Supplementary Table 4). The reﬁned structure contained four monomers of PltM
and 33 Hg atoms coordinated to Cys residues per asymmetric unit. A monomer of
PltM from this structure was then used as a search model to determine the
structure of native PltM by molecular replacement with Phaser38 in CCP4i suite39.
The native crystal structure of PltM was then iteratively adjusted and reﬁned by
using COOT36 and REFMAC537, respectively. Supplementary Table 4 contains
data collection and structure reﬁnement statistics for this and other crystal structures in this study. The crystal structure coordinates and structure factor amplitudes for all crystal structures were deposited in the Protein Data Bank under
accession codes speciﬁed in Supplementary Tables 4 and 5.
Structure determination for the PltM–FAD intermediate. PltM crystals were
soaked in the reservoir solution used to obtained native PltM crystals, with additional 0.5 mM of FAD. The crystals were then gradually transferred to the reservoir
solution with 20% v/v PEG 400 and 0.5 mM FAD, prior to quick immersion in

NATURE COMMUNICATIONS | (2019)10:1255 | https://doi.org/10.1038/s41467-019-09215-9 | www.nature.com/naturecommunications

9

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09215-9

liquid nitrogen. The diffraction data were collected and processed as described
above. Rigid body reﬁnement followed by restrained reﬁnement were performed
starting from the structure of apo PltM. FAD was readily discernable in the omit
Fo–Fc map. Reﬁnement and model building was carried out as described above.
Structure determination for the holo PltM–FAD complex. Wild-type PltM and
the L111Y mutant (each at 40 mg/mL) were crystallized by using the reservoir
solution composed of 0.1 M Tris, pH 8, 0.2 M NaBr, 0.1 M CaCl2, and 14% PEG
8000 (10% PEG 8000 in case of the PltM L111Y mutant). The crystals were gradually transferred to the cryoprotectant solution (0.1 M Tris, pH 8, 0.2 M NaBr, 1
mM FAD, 16% PEG 8000 (14% PEG 8000 for the PltM L111Y mutant), 20% PEG
400 and 1 mM FAD) and incubated overnight. Prior to rapid freezing via liquid
nitrogen, crystals were brieﬂy transferred to the cryoprotectant solution containing
additionally 0.2 M sodium dithionite. The crystal structures were determined by a
procedure analogous to that described above.
Structure determination for PltM–FAD–phloroglucinol complex. Native crystals
of PltM were transferred to reservoir solution with 0.5 mM FAD either without or
with 1 mM of phloroglucinol for 10 min, then to the cryoprotectant with the same
composition, additionally containing 20% v/v PEG 400. After an overnight incubation, the crystals were rapidly frozen in liquid nitrogen. We tested compounds 1,
2, 3, 8, 21, 23, and 24. Data collection, processing, and structure determination
were carried out as described above. FAD was clearly discernable in the omit Fo–Fc
electron density map. Out of all substrates tested, only compound 1 (phloroglucinol) yielded omit Fo–Fc electron density. Phloroglucinol was built into a very
strong and featureful polder omit mFo–DFc electron density25 in three out of four
substrate binding sites in the asymmetric unit (Fig. 4b in the main text).

Data availability
The crystal structure coordinates and structure factor amplitudes for all crystal structures
were deposited in the Protein Data Bank under accession codes 6BZN, 6BZI, 6BZA,
6BZQ, 6BZT and 6BZZ, as described in Supplementary Tables 4 and 5. NMR spectra,
LC-MS, and other chromatographic data are included in the raw format in
Supplementary Information. Other data are available from the corresponding authors
upon reasonable request.
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